genzyme corporation

Icahn Seeks Management Shake-Up at Genzyme

Despite the FDA's approval of Genzyme's Lumizyme, activist investor Carl Icahn is none too pleased with the company. In an SEC filing Wednesday, he asked the board to remove CEO Henry Termeer from his position as Chairman.

Stem Cell Therapies: Is Now the Time to Invest?

For investors on the hunt for groundbreaking technologies, stem cell therapies originally looked promising. But while the world waited for research to transform into treatments, Wall Street largely lost interest. Now, the science is accelerating, but stock prices haven't caught up. Is today your chance to make a killing on healing?

Genzyme's Problems Continue as FDA Takes Control of Plant

Following a series of manufacturing problems dating back to 2008, biotech company Genzyme announced the FDA will take enforcement action to ensure that products manufactured at its Allston plant in Boston are made in compliance with good manufacturing practice regulations.

2010 Could Be Big for Small Biotechs

Biotech stocks surprised in 2009 by surging. Equally surprising was the robust performance of the young and small-cap crowd of mostly development-stage companies, which trumped their large-cap brethren. That pattern could prevail again this year.

Health-Care Sector Appears to Rally As Reform Chances Dim

President Obama can't be pleased by the loss of a Democratic Senate seat which jeopardizes passage of his cherished health-care reform. The news, however, appears to have fueled a mini stock rally in the health-care and pharma sectors wary of how any reform would affect their businesses. The uptrend is expected to continue.